- Home
- TCRX vs INFU Comparison
TCRX vs INFU Comparison
Compare TCRX & INFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- INFU
- Stock Information
- Founded
- TCRX 2018
- INFU 2005
- Country
- TCRX United States
- INFU United States
- Employees
- TCRX N/A
- INFU N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- INFU Medical/Dental Instruments
- Sector
- TCRX Health Care
- INFU Health Care
- Exchange
- TCRX Nasdaq
- INFU Nasdaq
- Market Cap
- TCRX 90.5M
- INFU 104.4M
- IPO Year
- TCRX 2021
- INFU N/A
- Fundamental
- Price
- TCRX $1.27
- INFU $5.39
- Analyst Decision
- TCRX Strong Buy
- INFU
- Analyst Count
- TCRX 7
- INFU 0
- Target Price
- TCRX $9.86
- INFU N/A
- AVG Volume (30 Days)
- TCRX 389.5K
- INFU 123.2K
- Earning Date
- TCRX 05-06-2025
- INFU 05-08-2025
- Dividend Yield
- TCRX N/A
- INFU N/A
- EPS Growth
- TCRX N/A
- INFU 3654.89
- EPS
- TCRX N/A
- INFU 0.15
- Revenue
- TCRX $4,421,000.00
- INFU $137,582,000.00
- Revenue This Year
- TCRX $47.30
- INFU $10.91
- Revenue Next Year
- TCRX $74.30
- INFU $8.18
- P/E Ratio
- TCRX N/A
- INFU $36.63
- Revenue Growth
- TCRX N/A
- INFU 7.98
- 52 Week Low
- TCRX $1.02
- INFU $4.61
- 52 Week High
- TCRX $9.69
- INFU $9.97
- Technical
- Relative Strength Index (RSI)
- TCRX 37.62
- INFU 57.20
- Support Level
- TCRX $1.32
- INFU $4.67
- Resistance Level
- TCRX $1.65
- INFU $5.61
- Average True Range (ATR)
- TCRX 0.12
- INFU 0.22
- MACD
- TCRX -0.02
- INFU 0.11
- Stochastic Oscillator
- TCRX 0.00
- INFU 76.84
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About INFU InfuSystems Holdings Inc.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.